Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia Supported by the National Institute for Health Research and Cancer Research UK funding to the Barts ...
Data spans seven presentations across both solid tumors and hematologic malignancies, providing updates on the potential benefit these therapies may bring to patients. - Data from the elacestrant plus ...
Credit: Getty Images. Capivasertib is a potential first-in-class AKT inhibitor. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for capivasertib ...
Data spans seven presentations across both solid tumors and hematologic malignancies, providing updates on the potential benefit these therapies may bring to patients. Data from the elacestrant plus ...
CHICAGO -- Adding investigational capivasertib to fulvestrant extended survival in patients with aromatase inhibitor-resistant estrogen receptor (ER)-positive, HER2-negative advanced breast cancer, ...
LOUISVILLE, Ky.--(BUSINESS WIRE)--Onco360 ®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by AstraZeneca for Truqap ™ (capivasertib). Truqap ™ is an ...
It was determined that the capivasertib combination was unlikely to meet the 2 endpoints vs the comparator arm. AstraZeneca has made the decision to end the CAPItello-280 trial evaluating capivasertib ...
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...
In patients with hormone receptor (HR)-positive, HER2-negative tumors resistant to aromatase inhibitors, addition of the investigational AKT inhibitor capivasertib to fulvestrant (Faslodex) doubled ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results